Academic history
Andreas Burchert, MD, PhD, is the Deputy Clinical Director and a Senior Physician at the Philipps-University Marburg, Marburg, Germany.
Speaking on novel therapies for AML
Prof. Burchert’s primary research focus is on novel therapies for the treatment of acute myeloid leukemia (AML). In particular, Prof. Burchert has recently worked on a study investigating whether FLT3-ITD inhibition with sorafenib can prevent AML relapse.
